pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Dermatology

May 10, 2023

UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe USA - English USA - English

Mar 30, 2023

Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC USA - English USA - English APAC - English USA - Deutsch USA - español USA - Français

Mar 22, 2023

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

Mar 17, 2023

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting USA - English Israel - English

Jun 16, 2022

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

Nov 16, 2021

Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases

Oct 18, 2021

Sirnaomics to Present STP705, the Company's Lead Drug Candidate, for the Treatment of Cutaneous Squamous Cell Carcinoma in situ, at the 2021 Fall Clinical Dermatology Conference

Sep 28, 2021

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

Sep 27, 2021

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

May 3, 2021

MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F USA - English France - Français España - español Deutschland - Deutsch

May 3, 2021

MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F USA - English USA - Français USA - español USA - Deutsch

Feb 3, 2021

MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology USA - English USA - English

Feb 2, 2021

Sirnaomics to Present at Medical Dermatology Summit

Jan 5, 2021

Evommune to Present at 2021 Virtual Dermatology Summit

Oct 29, 2020

PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology

Mar 9, 2020

Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting

Jan 9, 2020

Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology

Nov 12, 2019

LEO Pharma Exercises Option with HitGen to License Compounds for Development of Novel Class of Drugs in Dermatology

Sep 12, 2019

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

May 13, 2019

Vyome Therapeutics Presents Positive Results from Two Key Clinical Trials at the 2019 Society for Investigative Dermatology Annual Meeting

May 7, 2019

Vyome Therapeutics to Present Clinical Data on VB-1953 at the 2019 Society for Investigative Dermatology Annual Meeting

Feb 18, 2019

Asana BioSciences to Present Correlation Between Microbiome Changes and Clinical Efficacy With JAK/SYK Inhibitor ASN002 in the Late-Breaking News Session at the American Academy of Dermatology (AAD) Annual Congress

Sep 10, 2018

Asana BioSciences to Present Late-Breaking Clinical and Biomarker Data for Its JAK/SYK Inhibitor ASN002 at the European Academy of Dermatology and Venereology (EADV) Annual Congress

Jun 13, 2018

PellePharm to Participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit

May 16, 2018

PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting

May 8, 2018

Asana BioSciences to Present Positive Clinical Efficacy and Skin Biomarker Data in Atopic Dermatitis Patients Treated with Its Novel Oral JAK/SYK Inhibitor, ASN002, at the International Investigative Dermatology Meeting

Feb 27, 2018

AIVITA Biomedical to Participate at Upcoming February and March Aesthetic & Dermatology Conferences

Jan 31, 2018

Asana BioSciences to Present Clinical Proof of Concept Study Results in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor, in the Late-Breaking Session at the American Association of Dermatology Annual Meeting

Jan 3, 2018

Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit

Mar 6, 2017

Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)

Mar 6, 2017

Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex

May 28, 2016

twoXAR Joins Stanford University in Hunt for Medicines Targeting Rare Diseases

Mar 7, 2016

Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology (AAD) Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia (AGA) Trial

Feb 17, 2016

Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedical

Mar 18, 2015

Blaze Bioscience Announces Poster Presentation at the American Academy of Dermatology 73rd Annual Meeting

May 9, 2014

Trevi Therapeutics Exhibits Poster at 2014 Annual Meeting of the Society for Investigative Dermatology